Nuclear HER4 Mediates Acquired Resistance to Trastuzumab and is Associated with Poor Outcome in HER2 Positive Breast Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2014 Aug 26

PMID 25153719

Citations 33

Authors

Siti Norasikin Mohd Nafi

Daniele Generali

Gabriela Kramer-Marek

Merel Gijsen

Carla Strina

Mariarosa Cappelletti

Daniele Andreis

Syed Haider

Ji-Liang Li

Esther Bridges

Jacek Capala

Roxanis Ioannis

Adrian L Harris

Anthony Kong

Affiliations

Soon will be listed here.

Abstract

The role of HER4 in breast cancer is controversial and its role in relation to trastuzumab resistance remains unclear. We showed that trastuzumab treatment and its acquired resistance induced HER4 upregulation, cleavage and nuclear translocation. However, knockdown of HER4 by specific siRNAs increased trastuzumab sensitivity and reversed its resistance in HER2 positive breast cancer cells. Preventing HER4 cleavage by a γ-secretase inhibitor and inhibiting HER4 tyrosine kinase activity by neratinib decreased trastuzumab-induced HER4 nuclear translocation and enhanced trastuzumab response. There was also increased nuclear HER4 staining in the tumours from BT474 xenograft mice and human patients treated with trastuzumab. Furthermore, nuclear HER4 predicted poor clinical response to trastuzumab monotherapy in patients undergoing a window study and was shown to be an independent poor prognostic factor in HER2 positive breast cancer. Our data suggest that HER4 plays a key role in relation to trastuzumab resistance in HER2 positive breast cancer. Therefore, our study provides novel findings that HER4 activation, cleavage and nuclear translocation influence trastuzumab sensitivity and resistance in HER2 positive breast cancer. Nuclear HER4 could be a potential prognostic and predictive biomarker and understanding the role of HER4 may provide strategies to overcome trastuzumab resistance in HER2 positive breast cancer.

Citing Articles

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer.

Azad A, Arshad M, Generali D, Feldinger K, Gijsen M, Strina C Cancer Commun (Lond). 2024; 45(1):68-73.

PMID: 39582148 PMC: 11758155. DOI: 10.1002/cac2.12632.

Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines.

Sanz-Alvarez M, Luque M, Morales-Gallego M, Cristobal I, Ramirez-Merino N, Rangel Y Int J Mol Sci. 2024; 25(1).

PMID: 38203378 PMC: 10779249. DOI: 10.3390/ijms25010207.

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2 breast cancer.

Debets D, Stecker K, Piskopou A, Liefaard M, Wesseling J, Sonke G Cell Rep Med. 2023; 4(10):101203.

PMID: 37794585 PMC: 10591042. DOI: 10.1016/j.xcrm.2023.101203.

Advances in understanding the role and mechanisms of tumor stem cells in HER2-positive breast cancer treatment resistance (Review).

Xu L, Han F, Zhu L, Ding W, Zhang K, Kan C Int J Oncol. 2023; 62(4).

PMID: 36866766 PMC: 9990588. DOI: 10.3892/ijo.2023.5496.

Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma.

Palumbo C, Benvenuto M, Focaccetti C, Albonici L, Cifaldi L, Rufini A Front Med (Lausanne). 2023; 10:1066021.

PMID: 36817764 PMC: 9932042. DOI: 10.3389/fmed.2023.1066021.

References

Veikkolainen V, Vaparanta K, Halkilahti K, Iljin K, Sundvall M, Elenius K . Function of ERBB4 is determined by alternative splicing. Cell Cycle. 2011; 10(16):2647-57. DOI: 10.4161/cc.10.16.17194. View

Portier B, Minca E, Wang Z, Lanigan C, Gruver A, Downs-Kelly E . HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma. Oncotarget. 2013; 4(10):1662-72. PMC: 3858553. DOI: 10.18632/oncotarget.1232. View

Linggi B, Carpenter G . ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional repression. J Biol Chem. 2006; 281(35):25373-80. DOI: 10.1074/jbc.M603998200. View

Rabindran S, Discafani C, Rosfjord E, Baxter M, Floyd M, Golas J . Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004; 64(11):3958-65. DOI: 10.1158/0008-5472.CAN-03-2868. View

Rio C, Buxbaum J, Peschon J, Corfas G . Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem. 2000; 275(14):10379-87. DOI: 10.1074/jbc.275.14.10379. View

Sundvall M, Peri L, Maatta J, Tvorogov D, Paatero I, Savisalo M . Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. Oncogene. 2007; 26(48):6905-14. DOI: 10.1038/sj.onc.1210501. View

Schott A, Landis M, Dontu G, Griffith K, Layman R, Krop I . Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res. 2013; 19(6):1512-24. PMC: 3602220. DOI: 10.1158/1078-0432.CCR-11-3326. View

Sundvall M, Korhonen A, Paatero I, Gaudio E, Melino G, Croce C . Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci U S A. 2008; 105(11):4162-7. PMC: 2393780. DOI: 10.1073/pnas.0708333105. View

Feng S, Sartor C, Hunter D, Zhou H, Yang X, Caskey L . The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation. Mol Endocrinol. 2007; 21(8):1861-76. PMC: 2917064. DOI: 10.1210/me.2006-0101. View

10.

Kainulainen V, Sundvall M, Maatta J, Santiestevan E, Klagsbrun M, Elenius K . A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem. 2000; 275(12):8641-9. DOI: 10.1074/jbc.275.12.8641. View

11.

Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi O, Elenius K . Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13(2):259-68. DOI: 10.1007/s10911-008-9079-3. View

12.

Ni C, Murphy M, Golde T, Carpenter G . gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science. 2001; 294(5549):2179-81. DOI: 10.1126/science.1065412. View

13.

Machleidt A, Buchholz S, Diermeier-Daucher S, Zeman F, Ortmann O, Brockhoff G . The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients. BMC Cancer. 2013; 13:437. PMC: 3849049. DOI: 10.1186/1471-2407-13-437. View

14.

Hollmen M, Liu P, Kurppa K, Wildiers H, Reinvall I, Vandorpe T . Proteolytic processing of ErbB4 in breast cancer. PLoS One. 2012; 7(6):e39413. PMC: 3382207. DOI: 10.1371/journal.pone.0039413. View

15.

Koutras A, Fountzilas G, Kalogeras K, Starakis I, Iconomou G, Kalofonos H . The upgraded role of HER3 and HER4 receptors in breast cancer. Crit Rev Oncol Hematol. 2009; 74(2):73-8. DOI: 10.1016/j.critrevonc.2009.04.011. View

16.

Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K . Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013; 4(10):1592-605. PMC: 3858548. DOI: 10.18632/oncotarget.1148. View

17.

Recupero D, Daniele L, Marchio C, Molinaro L, Castellano I, Cassoni P . Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. J Pathol. 2012; 229(3):390-9. DOI: 10.1002/path.4074. View

18.

Adilakshmi T, Ness-Myers J, Madrid-Aliste C, Fiser A, Tapinos N . A nuclear variant of ErbB3 receptor tyrosine kinase regulates ezrin distribution and Schwann cell myelination. J Neurosci. 2011; 31(13):5106-19. PMC: 3086203. DOI: 10.1523/JNEUROSCI.5635-10.2011. View

19.

Carraway K, Carraway C, Carraway 3rd K . Roles of ErbB-3 and ErbB-4 in the physiology and pathology of the mammary gland. J Mammary Gland Biol Neoplasia. 1997; 2(2):187-98. DOI: 10.1023/a:1026360032602. View

20.

Suo Z, Risberg B, Kalsson M, Willman K, Tierens A, Skovlund E . EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol. 2001; 196(1):17-25. DOI: 10.1002/path.1003. View